You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 18, 2026

AEROLONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Aerolone patents expire, and when can generic versions of Aerolone launch?

Aerolone is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in AEROLONE is isoproterenol hydrochloride. There are seventeen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the isoproterenol hydrochloride profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for AEROLONE?
  • What are the global sales for AEROLONE?
  • What is Average Wholesale Price for AEROLONE?
Summary for AEROLONE
US Patents:0
Applicants:1
NDAs:1

US Patents and Regulatory Information for AEROLONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly AEROLONE isoproterenol hydrochloride SOLUTION;INHALATION 007245-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
98https://www.drugpatentwatch.com/inc/modules/tools/ai_gpt_report.php?dashboard=alphasignals-sm§ion=drug&query=AEROLONE&subsorpreview=preview

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.